The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis
Clinical Microbiology and Infection · 2025
DOI: 10.1016/j.cmi.2025.08.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Tali Shafat und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electr…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Virus Activation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
OBJECTIVES: Epstein-Barr virus (EBV) reactivation following allogeneic haematopoietic cell transplantation (allo-HCT) is associated with increased mortality and possible posttransplant lymphoproliferative disorder. With the lack of prophylactic agents, identifying modifiable risk factors to prevent EBV-related mortality is desired. Cytomegalovirus (CMV) DNAemia has been previously associated with EBV DNAemia; the impact of letermovir prophylaxis on this association remains unclear. We aimed to identify risk factors for EBV reactivation; assess the correlation between EBV, CMV reactivation, and letermovir use; and assess the impact of EBV reactivation on mortality. METHODS: We conducted a retrospective cohort study of allo-HCT recipients between March 2016 and December 2019. We excluded patients lacking EBV PCR monitoring or with negative CMV recipient serostatus. A multivariable competing risks analysis was used to identify risk factors for EBV reactivation and mortality at week 48 posttransplantation. RESULTS: EBV reactivation occurred in 183 of 668 (27.4%) allo-HCT recipients; of those, 57 (31.1%) had significant EBV reactivation, and 10 (5.5%) were diagnosed with posttransplant lymphoproliferative disorder. EBV reactivation was associated with CMV DNAemia, clinically significant CMV infection, and CMV end-organ disease (49.7%, 48.1%, and 19.1% compared with 37.3%, 34.8%, and 9.7% with no EBV reactivation, respectively, all p < 0.05) and was not associated with letermovir primary prophylaxis (24.2% on vs. 29.7% off letermovir, p 0.118). In multivariable analysis, risk factors for EBV reactivation included CMV reactivation (adjusted hazard ratio (aHR) 1.46), Asian (aHR 2.00) or Black race (aHR 2.71), underlying acute myeloid leukaemia (aHR 1.98) or chronic myelomonocytic leukaemia (aHR 3.16), graft-vs.-host disease (aHR 2.35), and antithymocyte globulin exposure (aHR 5.90). A propensity score-adjusted multivariable analysis confirmed no significant association between letermovir prophylaxis and EBV reactivation. EBV reactivation was not independently associated with mortality. DISCUSSION: EBV reactivation had no apparent correlation with letermovir prophylaxis, was associated with previous CMV reactivation, and had no significant impact on mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tshafat@mdanderson.org.
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, TX, USA.
- Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Shafat, T., Khawaja, F., Jiang, Y., Daher, M., Febres-Aldana, A., Shigle, T. L., Rondon, G., Champlin, R., Bhatti, M., Spallone, A., Olson, A., Ariza-Heredia, E. J., Chen, G., Rezvani, K., Shpall, E. J., & Chemaly, R. F. (2025). The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.08.017
Vancouver
Shafat T, Khawaja F, Jiang Y, Daher M, Febres-Aldana A, Shigle TL, et al. The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2025.08.017
BibTeX
@article{Shafat2025,
author = {Shafat, Tali and Khawaja, Fareed and Jiang, Ying and Daher, Marilyne and Febres-Aldana, Anthony and Shigle, Terri Lynn and Rondon, Gabriela and Champlin, Richard and Bhatti, Micah and Spallone, Amy and Olson, Amanda and Ariza-Heredia, Ella J and Chen, George and Rezvani, Katayoun and Shpall, Elizabeth J and Chemaly, Roy F},
title = {The interplay between Epstein-Barr virus and cytomegalovirus reactivation following allogeneic haematopoietic cell transplantation in the era of primary cytomegalovirus prophylaxis},
journal = {Clinical Microbiology and Infection},
year = {2025},
doi = {10.1016/j.cmi.2025.08.017}
}
EUVIMED